English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Design and stability of pediatric oral formulation of imatinib (Hinterlang M et al. J Oncol Pharm Pract, March 2022)
Design and stability of pediatric oral formulation of imatinib
Hinterlang M et al. J Oncol Pharm Pract, March 2022
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML (Smith SM et al. Pediatr Hematol Oncol, December 2021)
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
Smith SM et al. Pediatr Hematol Oncol, December 2021 (epub ahead of print)
Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase (Lee JW et al. Blood Res, November 2021)
Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
Lee JW et al. Blood Res, November 2021
Comparison of the transcriptomic signature in pediatric and adult CML (Youn M et al. Cancers(Basel), December 2021)
Comparison of the transcriptomic signature in pediatric and adult CML
Youn M et al. Cancers(Basel), December 2021 – open access publication
Seven year long follow-up of patient with childhood chronic myeloid leukemia postsecond haploidentical stem cell transplant (Sachdev M et al. J Pediatr Hematol Oncol, November 2021)
Seven year long follow-up of patient with childhood chronic myeloid leukemia postsecond haploidentical stem cell transplant
Sachdev M et al. J Pediatr Hematol Oncol, November 2021
